The impact of concurrent granulocyte macrophage-colony stimulating factor on radiation-induced mucositis in head and neck cancer patients: A double-blind placebo-controlled prospective Phase III study by Radiation Therapy Oncology Group 9901

Ryu, Janice; Swann, S.; LeVeque, Francis G.; Scarantino, Charles W.; Johnson, Dennis R.; Chen, Allan; Fortin, A.; Pollock, Jondavid; Kim, Harold; Ang, K. Kian

doi:10.1016/j.ijrobp.2006.09.043

Cited by 59 publications

(28 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Eight controlled clinical trials were found using growth factors against oral mucositis 85,87,112,113,130,152 ; five by subcutaneous injection administration 26,31,85,87,112 , and three topically applied 113,130,152 . Three of the five studies that used subcutaneous injection showed statistically significant differences in irradiated patients 31,87 and in those treated with chemotherapy 26 .…”

Section: Bio-stimulantsmentioning

confidence: 99%

Cancer treatment-induced oral mucositis: a critical review

Rodríguez-Caballero

Torrés-Lagares

Robles-García

et al. 2012

International Journal of Oral and Maxillofacial Surgery

163

113

View full text Add to dashboard Cite

Head and neck cancer represents one of the main oncological problems. Its treatment, radiotherapy and chemotherapy leads to mucositis, and other side effects. The authors reviewed high-quality evidence published over the last 25 years on the treatment of cancer treatment-induced oral mucositis. A Medline search for double blind randomized controlled clinical trials between 1985 and 2010 was carried out. The keywords were oral mucositis, radiotherapy, chemotherapy, and head and neck. The different therapeutic approaches found for cancer treatment-induced oral mucositis included: intensive oral hygiene care; use of topical antiseptics and antimicrobial agents; use of anti-inflammatory agents; cytokines and growth factors; locally applied non-pharmacological methods; antioxidants; immune modulators; and homoeopathic agents. To date, no intervention has been able to prevent and treat oral mucositis on its own. It is necessary to combine interventions that act on the different phases of mucositis. It is still unclear which strategies reduce oral mucositis, as there is not enough evidence that describes a treatment with a proven efficiency and is superior to the other treatments for this condition.

show abstract

Section: Bio-stimulantsmentioning

confidence: 99%

Cancer treatment-induced oral mucositis: a critical review

Rodríguez-Caballero

Torrés-Lagares

Robles-García

et al. 2012

International Journal of Oral and Maxillofacial Surgery

163

113

View full text Add to dashboard Cite

show abstract

“…One study found a benefit of this drug in H&N cancer patients treated with CT [62]. Whereas some studies found a benefit for preventative use of systemic GM-CSF in H&N cancer patients undergoing (C)RT [63][64][65][66], others did not confirm such effect [67,68]. In addition, two studies indicated a benefit for systemically administered GM-CSF to prevent mucositis in the adult HSCT setting [69,70], although in the latter study, oral mucositis was not a primary outcome.…”

Section: Granulocyte Colony-stimulating Factormentioning

confidence: 99%

Systematic review of cytokines and growth factors for the management of oral mucositis in cancer patients

Raber-Durlacher

Bültzingslöwen²,

Logan

et al. 2012

Support Care Cancer

113

View full text Add to dashboard Cite

Purpose The aim of this project was to review the literature and define clinical practice guidelines for the use of cytokines and growth factor agents for the prevention or treatment of oral mucositis induced by cancer chemotherapy or radiotherapy. Care Cancer (2013) 21:343-355 DOI 10.1007/s00520-012-1594 following three guideline determinations was possible: Recommendation, Suggestion, No guideline possible. Results Sixty-four clinical studies across 11 interventions were evaluated. A recommendation was made for the use of recombinant human KGF-1 (palifermin) at a dose of 60 μg/kg per day for 3 days prior to conditioning treatment and for 3 days post-transplant for prevention of oral mucositis in patients receiving high-dose chemotherapy and total body irradiation followed by autologous stem cell transplantation for hematological malignancies. A suggestion was made against using granulocyte macrophage colony-stimulating factor mouthwash for the prevention of oral mucositis in the setting of high-dose chemotherapy followed by autologous or allogeneic stem cell transplantation. No guideline was possible for any other cytokine or growth factor agents due to inconclusive evidence. Conclusions Of the cytokine and growth factor agents studied for oral mucositis, the evidence only supports use of palifermin in the specific population listed above. Additional welldesigned research is needed on other cytokine and growth factor interventions and in other cancer treatment settings. Methods

show abstract

“…The treatments for oral mucositis includes: administration of topical antimicrobial agents [10], vitamins [11,12], growth factors [13,14], mouth washes [15], and cryotherapy [16,17].…”

Section: Introductionmentioning

confidence: 99%